Virtual Event

Healix is a proud exhibitor at IDWeek^TM 2020! Uniquely focused in infectious disease (ID) and supporting over 300 ID physicians across the country, we are the nation’s leader in providing physician office-based infusion services. Focused on patient and physician peace of mind for 30 years, we offer unparalleled capabilities for optimal patient care, comfort, compliance, and clinical outcomes in an outpatient setting.

Visit the Healix virtual booth during this year’s conference and speak with a representative October 22 – 24, 2020, to learn how we can help infectious disease practices like yours to provide unparalleled infusion patient care.

From our long-standing involvement in the infectious disease community, Healix also coordinates and conducts collaborative clinical research in the provision of Outpatient Parenteral Antimicrobial Therapy (OPAT) since 2008. While attending the conference, please visit the following Healix poster presentations with presenter audio available beginning October 21 in the IDWeek^TM ePoster Gallery:

#614: Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections and Bacteremia in Infectious Disease Outpatient Infusion Clinics

Brian S. Metzger, MD, MPH¹, Richard C. Prokesch, MD, FACP, FIDSA², Jorge R. Bernett, MD³, Richard M. Mandel, MD⁴, FIDSA, Ramesh V. Nathan, MD, FIDSA⁵, Kent J. Stock, DO⁶, Thomas C. Hardin, PharmD⁷, Claudia P. Schroeder, PharmD, PhD⁷, Lucinda J. Van Anglen, BS, PharmD⁷

¹Austin Infectious Disease Consultants, Austin, TX; ²Infectious Disease Associates, Riverdale, GA; ³Infectious Disease Doctors Medical Group, Walnut Creek, CA; ⁴Southern Arizona Infectious Disease Specialists, Tucson, AZ; ⁵Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA; ⁶Low Country Infectious Disease, Summerville, SC; ⁷Healix Infusion Therapy, Sugar Land, TX

#787: Evaluation of Clostridioides difficile Environmental Contamination Surrounding C. difficile Patients and non-C. difficile Patients in Outpatient Infusion Centers

Kevin W. Garey, PharmD¹, Richard L. Hengel, MD², Timothy E. Ritter, MD³, Ramesh V. Nathan, MD, FIDSA⁴, Claudia P. Schroeder, PharmD, PhD⁵, Gabriella Costa¹, Chris Lancaster¹, Engels N. Obi⁶, Lucinda J. Van Anglen, BS, PharmD⁵

¹University of Houston College of Pharmacy, Houston, TX; ²Atlanta ID Group, Atlanta, GA; ³GI Alliance, Southlake, TX; ⁴Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA; ⁵Healix Infusion Therapy, Sugar Land, TX; ⁶Merck & Co, Inc., Kenilworth, NJ

#1327: Vancomycin Dosing by AUC₂₄/MIC in Comparison to Traditional Trough Dosing in Office Infusion Centers (OICs)

Quyen Luu, MD¹, John S. Adams, MD, FIDSA, FSHEA², Brian S. Metzger, MD, MPH³, Richard L. Hengel, MD⁴, Rishi Bhattacharyya, MD⁵, David N. Rhoads, PharmD⁶, Kimberly A. Couch, PharmD⁶; Claudia P. Schroeder, PharmD, PhD⁶; Lucinda J. Van Anglen, BS, PharmD⁶

¹Central Georgia Infectious Diseases, Macon, GA; ²Knoxville Infectious Disease Consultants, PC, Knoxville, TN; ³Austin Infectious Disease Consultants, Austin, TX; ⁴Atlanta ID Group, Atlanta, GA; ⁵Infectious Disease Associates, Sarasota, FL; ⁶Healix Infusion Therapy, Sugar Land, TX

#1625: Real-World Outpatient Utilization of Ceftolozane/Tazobactam in Physician Office Infusion Centers (OICs)

Lucinda J. Van Anglen, BS, PharmD¹, Ramesh V. Nathan, MD, FIDSA², Brian S. Metzger, MD, MPH³, Quyen Luu, MD⁴, Claudia P. Schroeder, PharmD, PhD¹

¹Healix Infusion Therapy, Sugar Land, TX; ²Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA; ³Austin Infectious Disease Consultants, Austin, TX; ⁴Central Georgia Infectious Diseases, Macon, GA